Biosimilars: Similarities to Enoxaparin and the Elephant in the Room
This article was originally published in RPM Report
Executive Summary
FDA held a brief educational session on how it is approaching the biosimilars abbreviated pathway. In it, the agency’s Rachel Sherman touched on generic enoxaparin and how to track interchangeability.